Substance Use Disorder M&A Market During 1H 2024
The substance use disorder (SUD) specialty is often the most active submarket in the Behavioral Health Care (BHC) sector, and the first half of 2024 was no exception. According to data captured in the LevinPro HC database, 10 SUD deals were announced during the first six months of 2024, making up about 28% of all BHC deals announced during that time. 1H 2024 activity mirrored the activity witnessed in the first half of 2023, when SUD deals comprised 27% of all BHC deals announced. This consistency reflects sustained investor interest in the SUD treatment space. However, a comparison to the first half of 2022 (36% of BHC deals) and 2021 (34% of BHC deals), when SUD deal totals hit 21... Read More »
Are We Past the Healthcare Retail Peak?
The Pull-Back Strategy of Village MD The March 2024 announcement from Walgreens Boots Alliance to scale back nearly half of its VillageMD clinics has sent shockwaves through the retail healthcare field. This pull-back, coupled with similar moves by Walmart and hints of caution from other retailers like CVS Health, raises serious questions about the long-term viability of the entire model. When we first covered the retail healthcare space back in late 2022, the message from many industry experts was that retail healthcare was here to stay. But now, with the recent news of Walgreens planning to close 160 VillageMD clinics across several states, we can’t help but to wonder – has retail... Read More »
The 10 Multi-Billion Dollar Deals that Kicked off 2024
The first quarter of 2024 started the Healthcare M&A market off with a bang, with 13 transactions in the billion-dollar price range announced during the first quarter. This compares to Q1:23, when only six transactions exceeded $1 billion. More than half of the billion-dollar transactions announced during Q1:24 were in the Biotechnology sector. Acquirer Target Price Target Sector Novo Holdings A/S Catalent, Inc. $16,500,000,000 Other Services Gilead Sciences, Inc. CymaBay Therapeutics, Inc. $4,300,000,000 Biotechnology Health Care Service Corporation Cigna’s Medicare assets $3,700,000,000 Managed... Read More »
First Quarter 2024 Healthcare M&A Results
Overview When we spoke to advisors and analysts in 2023, they all expected “more of the same” for the healthcare M&A market in 2024. None of the headwinds from 2023 were expected to be resolved this year, and especially not by the first quarter. In mid-March, the Federal Reserve (again) declined to adjust interest rates, remaining at 5.25% to 5.5%. The Biden Administration and Federal Regulators remain skeptical of private equity investments in the healthcare and senior care markets and pledged to continue reviewing their activity throughout the year, challenging deals and mergers. Labor shortages continue to pressure healthcare organizations and providers. Hospitals have been hit... Read More »
Elevance Health Q4 2023 Earnings Snapshot
Elevance Health announced its earnings and revenue for the fourth quarter of 2023 on January 24, 2024. The health insurer and healthcare-services provider, formerly known as Anthem, posted a profit of $856 million, or $3.63 a share, compared with $865 million, or $3.59 a share, during Q4 2022. The company also announced $42.5 billion in revenue for Q4 2023, a 7% increase from the $39.9 billion in revenue reported for the prior year quarter. For the full year 2023, Elevance Health brought in $171.3 billion in revenue and $6 billion in profit. This compares to $156.6 billion in revenue and $5.9 billion in profit for 2022. Operating revenue for the full year was $148.6 billion,... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
